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Epidermal growth factor receptor expression is abnormal in murine
polycystic kidney. Renal tubular cyst formation and progressive enlarge-
ment in autosomal recessive polycystic kidney disease (ARPKD) are
mediated by increased epithelial cell proliferation and altered transtubular
fluid transport. Epidermal growth factor (EGF)-like peptides have been
proposed to play roles in normal nephrogenesis and cystic tubular
mitogenesis. Therefore, renal expression of EGF receptor (EGFR) pro-
tein and mRNA was examined in an animal model for ARPKD, the
C57BL/6Jcpk/cpk (CPK) mouse. Both quantitative and qualitative abnor-
malities of EGFR expression were demonstrated. While both control and
cystic proximal tubules, as well as control collecting tubules, demonstrated
exclusive basalateral EGFR protein expression, cystic collecting tubules
exhibited significant apical-lateral receptor localization. During nephro-
genesis, EGFR protein expression was elevated in CPK renal tissue when
compared to developmentally staged controls. Control and CPK kidneys
expressed the same species of EGFR mRNA. Levels increased with
developmental age, but were significantly higher at each stage of devel-
opment in CPK kidneys. Overexpression of both EGFR protein and
mRNA in CPK mice suggests altered control of EGFR protein and/or
gene expression. EGFR mislocalization and overexpression may be mech-
anisms whereby the EGF-like factors in cyst fluid stimulate cystogenesis
through an autocrine-paracrine cycle in ARPKD.
Polycystic kidney diseases (PKD) are a group of developmental
renal disorders that are characterized by progressive fluid accu-
mulation in dilated renal tubules to form cysts. Numerous large
cysts compromise the function of the remaining normal tubules
and eventually lead to renal failure. The two most common
inherited forms, autosomal recessive PKD (ARPKD) and auto-
somal dominant PKD (ADPKD), affect over 500,000 people in
the United States and are responsible for 8 to 10% of all patients
receiving dialysis or transplantation for end-stage renal disease
[1,21. The genes responsible for ARPKD and ADPKD have yet to
be identified, but recent reports link ARPKD to human chromo-
some 6 [3] and the gene responsible for approximately 85% of
ADPKD cases (P1(D1) has been identified on human chromo-
some 16 [4]. A number of in vivo and in vitro experimental models
have been used to examine the pathophysiology of renal cyst
formation and enlargement [5]. These studies, mathematical
analysis of cyst growth kinetics, and anatomical study of ADPKD
have shown that the three basic requirements for cyst formation
are altered transtubular fluid transport, abnormal extracellular
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matrix structure and function, and increased epithelial cell prolif-
eration [reviewed in 6].
Many polypeptide growth hormones have been identified that
have stimulatory or inhibitory effects on the proliferation of
epithelial and mesenchymal cells [reviewed in 6]. Several of these
growth factors: epidermal growth factor, insulin-like growth fac-
tors, transforming growth factors, platelet-derived growth factor,
and the fibroblast growth factors (EGF, IGFs, TGFs, PDGF, and
FGFs), have been implicated in normal renal organogenesis,
based on observations that the growth factors and their receptors
are found within the developing kidney. Evidence has accumu-
lated that suggests a role for EGF and its receptor (EGFR) in
PKD. In mouse and rat models for congenital PKD, defective
EGF precursor gene expression has been reported [7, 8]. Human
and murine PKD cyst fluid also contains elevated levels of EGF
and EGF-like peptides compared to urine [9]. Cyst wall epithelial
are hypersensitive to EGF-induced mitogenesis in some [10], but
not all reports [11]. In addition, EGF and TGF-a, both of which
utilize the same receptor, have been found to be renal mitogens
that induce abnormal epithelial hyperplasia and solute transport
in both murine metanephric organ culture and in normal human
kidney cells in culture, leading to cyst formation [12, 13]. Recently,
EGF and TGF-a induced cyst formation was found to be medi-
ated by EGFR tyrosine kinase activity [14]. Therefore, we have
chosen to study the possible role of the EGFITGF-cs/EGFR
system in abnormal cell proliferation in PKD.
The present study uses an animal model of ARPKD, the
C57BLI6JcpkIcpk (CPK) mouse, that arose from a spontaneous
mutation in the C57 BL/6J (C57) strain [15]. Controlled breeding
of obligatory heterozygotes has maintained the cystic CPK strain.
Although animals appear normal at birth, they develop progres-
sive lethargy, abdominal protuberance and wasting, and die in
renal failure by four weeks of age with massively enlarged kidneys.
The earliest signs of cystic disease are evident in proximal tubules
on embryonic day 17. As the disease progresses, the site of cystic
involvement shifts from proximal tubules to cortical and outer
medullary collecting tubules [reviewed in 2].
The shift in nephron involvement during renal organogenesis
suggests that there may be a developmentally regulated pattern of
cystic gene expression or tubular responsiveness to cyst-promoting
processes. To determine if there are abnormalities in renal EGFR
expression that might provide a mechanism for EGF and EGF-
like factors to lead to cyst formation in P1(D, EGFR antibodies
were used to localize the EGFR protein in specific tubular
segments and murine probes were used to characterize receptor
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mRNA expression during development. The results of these
studies suggest that there may be altered control of intracellular
protein sorting as well as altered regulation of the EGFR at both
the gene and protein levels in CPK mice exhibiting cystic disease.
Methods
Tissue preparation
As previously described [16], control C57 and cystic CPK mice
were sacrificed to obtain kidney tissue at four postnatal stages:
days 0 (newborn), 7, 14, and 21. In this model, day 0 corresponds
to a stage of predominant proximal tubule cyst development, and
days 7, 14, and 21 correspond to progressive stages of collecting
tubule cyst development. Tissue was fixed, and serial sections were
cut parallel to the long axis of the kidney.
Markers for proximal and collecting tubules were as described
[16]. Briefly, the lectins Lotus tetragonologbus agglutinin (LTA)
and Dolichos bifiorus agglutinin (DBA) were used as markers for
proximal and collecting tubules, respectively. Proximal tubules are
LTA(+)/DBA(—), and collecting tubules are LTA(—)/DBA(+).
Immunohistochemical localization of the EGFR
The cellular location of the EGFR was determined by immu-
nohistochemical staining of C57 and CPK kidney sections with
either of the monoclonal EGFR antibodies, F-4 (Sigma, St. Louis,
MO, USA) or HB 8506 (American Type Tissue Collection,
Rockville, MD, USA), or the rabbit antiserum, RK-2 [17], as
described [16, 18]. F-4 is an IgGi class antibody derived from mice
immunized with a synthetically produced peptide corresponding
to cytoplasmic residues 985-996 of the EGFR conjugated to
keyhole limpet hemocyanin. The antibody HB 8506 is derived
from mice immunized with partially purified EGFR from human
epidermoid carcinoma A431 cells and blocks EGF binding to
receptor and growth of A431 cells in culture. The RK-2 antibody
is directed against a synthetic peptide from the cytoplasmic
domain of the EGFR. All antibodies cross react with human and
mouse EGFR. In addition, the three antibodies had identical
EGFR immunostaining patterns in all kidney sections tested.
Membrane labeling with EGF-biotin
The cellular location of EGFR ligand binding sites was deter-
mined by incubating CPK kidney sections with biotinylated EGF.
Kidneys from 7 and 14 day CPK mice were sliced into 150 micron
sections and placed in Trowell culture dishes [19]. Slices were
incubated for 20 minutes at 20°C in basal medium [19] containing
50 ng/ml EGF-biotin (Boehringer Mannheim Corp., Indianapolis,
IN, USA), or 50 ng/ml EGF as a negative control. Slices were
washed twice with basal medium for five minutes at 4°C. Samples
were then incubated with 10 tg/ml extraviden peroxide, in basal
medium, for 30 minutes at 4°C. Two 10 minutes washes with basal
medium were followed by an additional two 10 minutes washes
with phosphate-buffered saline (PBS: 150 mrvi NaCl, 10 mM
sodium phosphate, pH 7.6), at 4°C. Slices were fixed for 15
minutes at 4°C with 4% paraformaldehyde, and then rinsed twice
for 10 minutes at 4°C with PBS. Samples were then incubated with
diaminobenzidine/H202 [19] in PBS for 10 minutes, washed twice
with PBS, dehydrated, infiltrated, and embedded for sectioning as
described [16, 18].
Identification of EGFR protein
The size of immunoreactive protein in C57 and CPK kidneys
was determined by Western analysis. Kidneys were homogenized
in RIPA buffer [10 m sodium phosphate, pH 7.2; 150 mst NaC1;
0.1% sodium dodecyl sulfate (SDS); 1% NP4O; 1% deoxycholate]
supplemented with 10 tM leupeptin, 70 xM pepstatifl, 1 mM
(4-amidinophenyl)-methane sulfonyl fluoride, 1.5 /LM aprotinin,
and 1 mvi EDTA. Samples (32 ig) were subjected to electro-
phoresis on 7.5% SDS-polyaciylamide gels [20] and blotted to
nitrocellulose with a Hoefer Transphor Electrophoresis unit
(Hoefer, San Francisco, CA, USA). Blots were probed with the
EGFR antibodies described above, and specific EGFR protein
was detected with ECL (Amersham, Arlington Heights, IL, USA)
according to the manufacturer's protocol.
RNA isolation
Total kidney RNA was isolated for use in hybridization analyses
and for cloning, using a modification of the guanidine hydrochlo-
ride method previously described [21]. Following dissection, C57
and CPK kidneys were either placed in ice-cold 8 M guanidine
hydrochloride; 25 m sodium acetate, pH 5, and immediately
disrupted with a Polytron, or frozen on dry ice and stored at
—70°C prior to homogenization. RNA was precipitated for 20
minutes on ice with 0.6 volumes of absolute ethanol. Precipitates
were centrifuged, and pellets were washed twice with 70% etha-
nol. Pellets were resuspended in guanidine hydrochloride/sodium
acetate and reprecipitated with absolute ethanol for one hour on
ice. Precipitates were centrifuged, washed three times with 70%
ethanol, dried, and resuspended in 25 p.M EDTA, 1 mrvi Tris, pH
8.3. Following a phenol/chloroform extraction, samples were
precipitated twice with two volumes of absolute ethanol, centri-
fuged, washed, and finally resuspended in water and stored at
—70°C.
For experiments, poly (At) RNA was isolated chromatograph-
ically over oligo (dT) cellulose [22]. RNA in solution was quan-
titated by measuring absorbance at 260 nm.
EGFR cDNA cloning
Complementary DNA corresponding to part of the amino-
terminal, extracellular region of the EGFR was cloned by PCR
amplification [22] based on the partial mouse cDNA sequence
described previously [23]. The 21-base oligonucleotide 5'-
CTCTCTCGGGGCCCTGTACACC-3' (3'-end primer) was used
as a primer for reverse transcription of day 7 C57 kidney poly
(At) RNA in order to generate EGFR cDNA. This sequence
corresponds to a region surrounding an Apal site approximately
883 bases from the beginning of the partial mouse EGFR eDNA
[23]. Poly (At) RNA (1 p.g) was heated for two minutes at 70°C,
and then mixed with the following reagents to achieve a final
volume of 20 p.1: 8 p.M 3'-end primer; 50 mrvi Tris-HC1, pH 8.3; 75
mM KC1; 3 mrvi MgCl2; 10 mM dithiothreitol (DYF); 0.5 m each
dGTP, dCTP, dTT'P, dATP; and 1 U/p.l Moloney murine leuke-
mia virus reverse transcriptase. The sample was incubated for 60
minutes at 37°C, ethanol precipitated, and resuspended in 60 p.1
water.
A second 25-base oligonucleotide was used to provide the 5'
end primer for PCR amplification of the EGFR cDNA:
5 '-CTGCCAAGGCACTAGTAACAGGCTC-3' (5 '-end primer).
The single underlined base change introduced a novel Spel site,
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259 bases from the beginning of the partial mouse cDNA [23],
into the amplified sequence for later subcloning. This base change
does not alter the predicted amino acid sequence. C57 kidney
cDNA, prepared as described above, was used as a template in the
PCR to amplify a 647bp fragment that included the novel Spel
restriction site of the 5'-end primer and theApal site of the 3'-end
primer. Both 5'- and 3'-end primers (1 MM) were mixed with 10 itl
of the cDNA generated by reverse transcription and incubated
with 10 mrvi Tris-HCI, pH 8.3; 50 mr's KC1; 1.5 mM MgCl2; 0.2 mM
each dGTP, dCTP, dTFP, dATP; and 0.01% gelatin in a total
volume of 99 M1. for two minutes at 94°C. One half unit of Taq
polymerase (Stratagene, La Jolla, CA, USA) was added, and the
sample was incubated in a Perkin-Elmer Thermal Cycler for 40
cycles (1 mm each at 94°C, 55°C, and 72°C). The resulting PCR
fragment was prepared as described [22] and then cut with Spel
and Apal to generate a 624 bp fragment that was subcloned into
Spel and Apal sites of the plasmid KS + (Stratagene). Restriction
mapping confirmed that the PCR-amplified fragment was the
murine EGFR reported by Avivi et al [23].
Riboprobe preparation
Plasmid containing the SpeIlA pal mouse EGFR cDNA in KS +
was amplified as described [221. For Northern analysis, the
plasmid was linearized at the Sad site in KS + to generate the
entire PCR-amplified cDNA, under the control of the T3 pro-
moter, as a template for synthesis of an antisense 32P-labeled
EGFR riboprobe. Linearized plasmid (0.5 Mg) was mixed with 40
mM Tris-HC1, pH 7.5; 6 mtvi MgC12; 2 mi spermidine; 10 mM
NaCl; 5 mrvi DTF; 0.4 m each GTP, CTP, ATP; 0.1 mCi
a32P-UTP (800 Ci/mmol); 40 units placental RNAsin (Promega,
Madison, WI, USA); and 10 units T3 RNA polymerase in a final
volume of 20 d. The sample was first incubated for 30 minutes at
37°C, then 1 to 2 ng DPRF DNAaseI (Worthington Biochemical
Corporation, Freehold, NJ, USA) was added and the sample was
incubated an additional 15 minutes. A solution comprised of 7%
SDS, 0.07% bromophenol blue, and 33% glycerol was added to
stop the reaction, and 32P-labeled riboprobe was separated from
unincorporated radionucleotides by chromatography over a Seph-
adex 0-75 column [22]. For ribonuclease protection analysis, a
shorter, 0.235 kb antisense riboprobe was synthesized by linear-
izing the EGFR cDNA plasmid with Afilil prior to 32P-labeling as
above.
As an internal control, a 32P-labeled human glyceraldehyde-3
phosphate dehydrogenase (G3PDH) riboprobe was also synthe-
sized. Reaction conditions were as described above, with the
following changes: 0.5 jxg of human G3PDH cDNA (Clontech,
Palo Alto, CA, USA) was used as template, and 25 units of T7
RNA polymerase (New England Biolabs, Beverly, MA, USA)
were used in place of the T3 enzyme.
Northern analysis of mRNA expression
In order to identify mouse kidney EGFR species, kidney
mRNA was subjected to Northern analysis. Poly (At) RNA (6
Mg) from 7 day C57 and CPK kidneys was prepared as described
above. Samples, and a 0.24 to 9.5 kb RNA standard ladder
(GIBCO/BRL, Gaithersburg, MD, USA), were heated for five
minutes at 70°C in 2.9% glycerol; 0.01% bromophenol blue;
0.01% xylene cyanol; 2.4 mrvi 3-[N-morpholino}propane-sulfonic
acid (MOPS), pH 7; 0.1 mrvi EDTA; 0.6 mM sodium acetate; 7.6%
formaldehyde; and 59% formamide. Samples were subjected to
electrophoresis through a 1.2% agarose gel containing 0.73%
formaldehyde; 1.96 mi MOPS, pH 7; 0.1 mM EDTA; and 0.5 mM
sodium acetate, in a buffer comprised of 2 mtvi MOPS, pH 7; 0.1
mM EDTA; and 0.5 m sodium acetate. The RNA ladder lane was
cut off and stained with ethidium bromide to visualize standard
fragments. Sample mRNA was transferred to a Hybond-N nylon
membrane (Amersham) as described [22]. Hybridization condi-
tions were the same as previously described [22] except that
temperatures for riboprobe hybridizations were 67°C for the
EGFR probe, and 65°C for the G3PDH probe, both of which are
described above. The blot was washed briefly at room tempera-
ture in 0.5x SSC (75 mti NaC1; 7.5 mri sodium citrate, pH 7),
0.2% SDS; once at 70°C for 15 minutes in 0.5x SSC, 0.2% SDS;
once at 70°C for 15 minutes in 0.25x SSC, 0.2% SDS; and once at
65°C for 15 minutes in 0.1x SSC, 0.2% SDS. Messenger RNA
species were visualized by autoradiography.
Ribonuclease protection analysis of mRNA expression
In order to compare relative levels of EGFR expression in the
mouse kidney, C57 and CPK RNA samples were analyzed by
ribonuclease protection assay at days 0, 7, 14, and 21. Total RNA
(5 Mg) was hybridized with the 0.235 kb 32P-labeled EGFR
antisense riboprobe described above (10 cpm/sample) in 50 M1
of 80% formamide; 1 msi EDTA; 400 mi NaCI; and 40 mM
piperazine-N,N'-bis [2-ethanesulfonic acid], pH 6.4. Samples were
denatured at 90°C for five minutes and incubated at 50°C over-
night. Unhybridized probe was digested at 30°C for one hour with
10 g/ml RNase A and 2400 U/mi RNase Ti in 500 M' of 5 mrvi
EDTA; 300 mtvi NaC1; and 10 mri Tris, pH 7.5. Samples were then
treated with proteinase K (100 g/ml) in 0.6% SDS at 45°C for 30
minutes. After the addition of 25 g of yeast transfer RNA as a
carrier, samples were extracted with equal volumes of a mixture of
50% phenol; 48% chloroform; and 2% isoamyl alcohol. Hybrid-
ized RNA fragments were precipitated with ethanol and then
separated by electrophoresis on a denaturing 8% acrylamide, 8 M
urea gel. The gel was dried and protected fragments were
detected by autoradiography. Fragment sizes were determined
after comparison to a 1 kb ladder (GIBCO/BRL) that had been
32P-labeled by T4 polynucleotide kinase according to the manu-
facturer's protocol. The expected size of the protected fragment
was 0.213 kb, which differed from the unhybridized probe by 22
bases.
In order to confirm uniform sample loading, parallel RNA
samples were loaded onto a formaldehyde/agarose gel, blotted to
a Hybond membrane, and subjected to Northern analysis with a
32PG3PDH riboprobe as described above. Quantitation of the
ribonuclease protection assay signal was performed by densitom-
etry using a Biolmage Visage 110 densitometer system (Millipore,
Bedford, MA, USA). The integrated optical densities of each
protected fragment band were normalized to the integrated
optical density of the corresponding G3PDH bands from the
Northern blot.
Materials
All other materials and reaction components were either re-
agent or molecular biology grade from New England Biolabs
(Beverly, MA, USA); GIBCO/BRL, and Sigma.
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Fig. 1. The nonnally basalateral EGFR is mislocated to apical-lateral
surfaces in CPK collecting tubules. Seven day C57 and CPK kidney sections
were immunostained with the EGFR antibody, HB 8506, as described in
the Methods. The concentration of antibody used was 936 j.sg/ml for C57
samples and 156 jig/mI for cystic samples. A. C57 proximal tubule. B. C57
collecting tubule. C. CPK proximal tubule. D. CPK collecting tubule. E.
CPK collecting tubule stained with the EGFR antibody RK-2. Data are
representative of at least 20 experiments. Original magnification in A and
B is 330X, in C is 200X, in D is lOOX, and in B is 100X.
Results
Cellular Distribution of EQFR
Control C57 and CPK proximal and collecting tubules were
identified by their lectin profile and the cellular location of the
EGFR was determined by immunohistochemistry. At all ages
examined, both C57 and CPK (unaffected and cystic) LTA(+)/
DBA(—) proximal tubules showed only basalateral distribution of
the EGFR (Fig. 1, A and C). No EGFR expression was detected
on the apical surface of either C57 or CPK proximal tubules. In
C57 LTA(—)/DBA(+) collecting tubules, EGFR distribution was
also exclusively basalateral (Fig. 1B). In contrast, CPK kidneys
showed EGFR expression on the apical surfaces of cystic collect-
ing tubules (Fig. 1D), as well as basalateral staining. Unaffected
CPK collecting tubules had only basalateral staining (Fig. 1D).
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Table 1. Apical-lateral EGFR expression increases with age in CPK
collecting tubules
Day %
0 ND
7 69±4.5
14 82±6.3
21 63±3.9
CPK sections were prepared and immunostained with the EGFR
antibody, HB 8506, as described in Methods and in the legend to Fig. 1.
EGFR expression is indicated by the percentage of collecting tubule cysts
showing apical-lateral staining in relation to the total number of collecting
tubule cysts analyzed. Values are the mean STD of n = 4 kidneys, 5
slices per kidney. ND, not determined because collecting tubule cysts are
rare at day 0. C57 sections were not analyzed since no apical staining was
found at any age.
Table 2. EGFR ligand binding is apical-lateral in CPK kidneys
Day %
0 ND
7 61±3.4
14 71±2.8
21 ND
CPK sections were prepared and incubated with the EGF-biotin, as
described in Methods. Receptor binding is indicated by the percentage of
collecting tubule cysts showing apical-lateral EGF-biotin binding in rela-
tion to the total number of collecting tubule cysts analyzed. Values are the
mean STDof 1 kidney each, 5—6 slices per kidney. ND, not determined.
C57 sections were not analyzed since no apical EGF-biotin binding was
found at any age.
Fig. 2. EGFR ligand binding is apical-lateral in CPK kidneys. CPK sections
were prepared and incubated with EGF-biotin, as described in Methods.
The figure shows EGF-biotin labeling of 7 day CPK collecting tubules.
Original magnification is 200x.
Immunostaining patterns were identical with EGFR antibodies
HB 8506 (Fig. 1D), RK-2 (Fig. 1E), and F-4 (data not shown).
Therefore, EGFR distribution in control and CPK proximal
tubules is identical and occurs only basalaterally, while in collect-
ing tubules, only CPK kidneys exhibit apical as well as basalateral
EGFR.
In the CPK mouse, renal cyst size dramatically increases with
age until at the terminal stages of disease, the kidney appears to
be comprised solely of large, fluid-filled cysts. As shown in Table
1, the percentage of CPK collecting tubule cysts that displayed
apical-lateral EGFR immunostaining increased to 82% by day 14.
No apical staining occurred in C57 collecting tubules at any
developmental stage studied (Fig. 1B), and collecting tubule cysts
were not present in CPK tissue at day 0. Therefore, abnormal
apical-lateral EGFR distribution in CPK collecting tubules in-
creased with developmental age.
EGFR ligand binding
The antibodies utilized in the immunohistochemical studies
described above recognized both intracellular and extracellular
regions of the EGFR. To determine if the misplaced, apical-
lateral EGFR found in cystic CPK collecting tubules recognized
the appropriate extracellular ligand, receptor binding was exam-
ined with the biotinylated ligand, EGF-biotin. As shown in Table
2, 61—71% of the CPK collecting tubule cysts displayed apical-
lateral EGF-biotin binding. In addition, the patterns of specific
EGF-biotin labeling (Fig. 2) and EGFR immunostaining (Fig.
1D) in CPK collecting tubules were identical. These data suggest
that proteins with EGF-binding capacity and with intracellular
Fig. 3. CPK collecting tubules overexpress the EGFR. Sections were immu-
nostained with the EGFR antibody, HB 8506, as described in the Methods
with an antibody concentration of 156 Lg/m1. A. C57 collecting tubule. B.
CPK collecting tubule. Original magnification is 200x.
EGFR domains co-localize on the apical-lateral surfaces of CPK
collecting tubules.
EGFR protein expression and identification
In order to compare levels of EGFR expression in C57 and
CPK kidney, immunostaining at a low antibody titer was utilized
to detect qualitative differences in expression levels. As shown in
Figure 3, EGFR was barely detectable in C57 collecting tubules,
while staining intensity was greater in CPK collecting tubules
using the same antibody titer. This observation suggests that the
EGFR is overexpressed in CPK tissue.
Therefore, to determine if CPK kidneys had altered forms or
quantities of the EGFR protein, Western analysis of total kidney
proteins was performed with tissues from 0, 7, 14, and 21 day mice
(Fig. 4). Monoclonal and polyclonal antibodies directed against
intracellular and extracellular regions of the EGFR demonstrated
that both C57 and CPK kidneys expressed a single 170-kilodalton
r
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mRNA in CPK kidney may be processed differently from control
at the level of either transcription or mRNA stability.
Discussion
1170,000
Fig. 4. Both control and CPK kidneys express a 170,000 Da EGFR protein.
Protein from C57 and CPK kidneys was subjected to Western analysis with
the EGFR antibody RK-2, as described in the Methods. The apparent
molecular weight of the immunoreactive band, in Daltons, is indicated.
Autoradiograph is representative of 3 experiments.
immunoreactive EGFR protein (Fig. 4). The resulting bands
co-migrated with purified EGFR (Promega) and with the EGFR
from A431 cells (data not shown). As shown, C57 kidney tissues
expressed constant levels of EGFR protein at all ages. In contrast,
in CPK tissue EGFR expression was greatest at 7 days, decreased
modestly at 14 and 21 days, and at all ages was overexpressed
relative to C57 levels. These data suggest that regulation of
protein stability may be altered in CPK kidney. The EGFR
protein was derived primarily from renal tubular epithelial cells,
based on the observed pattern of EGFR expression seen in the
immunohistochemical sections taken from C57 and CPK kidneys
(Figs. 1—3). Therefore, both C57 and CPK tubular epithelia
expressed a single immunoreactive protein corresponding to the
EGFR, suggesting that the EGFRs present on the basalateral and
apical surfaces of CPK collecting tubules are similar.
Expression of EGFR mRNA
Overexpression of EGFR protein and the existence of differ-
entially localized EGFR proteins in the CPK mouse suggest that
there may be: (a) overexpression of EGFR mRNA; (b) altered
species of EGFR mRNA or protein; or (c) altered stability of
EGFR mRNA or protein. An increase in expression or stability of
EGFR mRNA might lead to increased translation of EGFR
protein. A mutation at the gene level in the promoter region of
the EGFR, or in a regulatory factor, might lead to the appearance
of multiple, differentially regulated mRNA species. A coding
sequence mutation could lead to altered stability or sorting of a
mutant EGFR protein. To address the possibility of altered
EGFR gene regulation, C57 and CPK kidneys were screened for
EGFR mRNA expression. Both C57 and CPK kidneys contained
three species of EGFR mRNA (Fig. 5). The predominant EGFR
mRNA species in both tissues was 6.4 kb, with less intense 10 kb
and 2.7 kb species. These sizes are similar to the 10.5, 5.8, and 2.8
kb mRNA species seen in human A431 cells [24, and Orellana and
Neff, unpublished observations]. In addition, the largest two
species correspond to those previously identified in murine kidney
using a genomic probe to the 3' domain of the EGFR [25].
Therefore, both C57 and CPK kidneys expressed identically
spliced versions of the EGFR gene.
The more sensitive ribonuclease protection assay, which groups
together all hybridizing EGFR mRNA species, showed that
overall receptor mRNA expression increased with age in both C57
and CPK kidneys (Fig. 6). EGFR mRNA expression was elevated
in CPK kidney, compared to C57, at all ages; differences in
expression ranged from approximately 2.7-fold at 0 days to 4.1
fold at 21 days (Fig. 7). These data suggest that the receptor
In the CPK mouse, a murine model for ARPKD, the EGFR is
mislocated to the apical-lateral surfaces of renal tubular epithe-
hum and both receptor protein and mRNA are overexpressed in
kidney tissue. In addition, there are differences in the develop-
mental patterns of EGFR protein and mRNA expression. These
data suggest that intracellular protein trafficking and control of
both EGFR gene and protein regulation are altered in CPK mice
exhibiting cystic disease.
The genetic forms of PKDdo not appear to involve a general-
ized deregulation of mechanisms involved in the polarized sorting
of membrane proteins. However, an abnormal, apical-lateral
pattern of expression has been observed previously for the
sodium/potassium adenosine triphosphatase (Na /K -ATPase)
in the CPK mouse [16]. In the cystic CPK kidney, apical Nat'K-
ATPase has been proposed to provide a mechanism for the
abnormal transtubular fluid transport seen in cystic disease. The
Na'1K-ATPase is normally expressed basalaterally in the mu-
rifle kidney, except for a transient expression on the apical surface
of collecting tubules early in development. The murine EGFR is
also transiently expressed on the apical surface of proximal, but
not collecting, tubules in developing fetal kidney [Avner and
Sweeney, unpublished observations]. However, the apical cell
surface markers GP-135, y-glutamyl transpeptidase, LTA, and
DBA; the basalateral marker ZO-1; and the basement membrane
markers type IV collagen, laminin, and entactin are unaffected
[16]. In addition, both the Nat'K-ATPase and the EGFR are
expressed properly in both morphologically normal and cystic
CPK proximal tubules. The existence of an immature pattern of
some polarized membrane proteins in the collecting tubules of the
CPK mouse has been proposed as a sign that the epithehial cells
lining cysts may be relatively undifferentiated in PKD. Similar
patterns of expression are seen in other models for congenital
PKD. The BPK mouse, a mutant line similar to CPK that also has
hepatic lesions, has apical-lateral EGFR [Avner and Sweeney,
unpublished observations] and Nat'K-ATPase [26]. A trans-
genie mouse created by insertional mutagenesis, TG737, has
apical-lateral EGFR, and some apical NaVK-ATPase [27]. In
human ARPKD, the EGFR, but not the Na/K-ATPase, is
distributed to the apical-lateral side of renal collecting tubular
epithelium [28]. In human ADPKD however, the EGFR, Nat'
K-ATPase, ankyrin, and fodrin have been reported to be mis-
sorted [10, 29], a pattern which is not seen at any distinct stage of
nephron development.
Although preliminary studies in MDCK cells suggest that
EGFRs are sorted to the basalateral surface [30], the mechanism
that regulates polarized sorting of the murine renal EGFR is not
known. Several distinct sorting processes have been reported for
other membrane proteins, and these possible mechanisms are
addressed as follows. (1) The EGFR may initially be sent to both
cell surfaces by bulk flow, as has been reported for FcRII-B1 and
Na'7K-ATPase [31, 32]. EGFR overexpression in CPK collect-
ing tubules may direct a significant amount of receptor to the
apical surface, where it may be retained and stabilized in the
apical membrane, as for the Nat'K-ATPase [16]. (2) There are
specific signals on several epithelial membrane proteins that
direct polarized sorting of these proteins to either apical or
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Fig. 5. C57 and CPK kidneys express the same EGFR mRNA species. Poly
(A+) RNA from 7 day C57 and CPK kidneys was subjected to Northern
analysis as described in the Methods. Autoradiograph is representative of
5 experiments. A. Blot was probed with the EGFR riboprobe as described
in the Methods. Standard sizes, in kb, of a 0.24-9.5 kb RNA ladder
(GIBCO/BRL) are indicated on the left. The sizes of the EGFR mRNA
species, in kb, are indicated on the right. B. The same blot used above was
reprobed with the G3PDH riboprobe as described in the Methods. Size, in
kb, is indicated.
basalateral cell surfaces [reviewed in 33]. Mutations or defects in
the signals lead to altered protein sorting, as demonstrated by the
low density lipoprotein receptor and the poly IgA receptor. Both
are normally targeted to the basalateral membrane by a specific
signal which when deleted, sends the protein to the apical
membrane [34, 35]. While amino acid sequences in the cytoplas-
mic domain of the EGFR are not perfect matches for the reported
basalateral targeting signals, there are regions of similarity. (3) In
MDCK cells, apical sorting appears to be directed by the presence
of glycosyl phosphatidylinositol moieties in the protein that
specify apical delivery of the newly synthesized protein to the
apical surface and serve as anchors [reviewed in 33]. A mutation
in the CPK EGFR that altered glycosylation might direct the
EGFR apically in cystic collecting tubules. (4) A defective protein
involved in polarized sorting that would normally recognize a
putative sorting signal on the EGFR might allow receptor to be
sent to both surfaces. The observation that the Na47K-ATPase is
missorted in the CPK model suggests that this is also a possibility.
Further experiments are required to determine the normal regu-
latory mechanisms for EGFR sorting.
Murine EGFR mRNA expression has been reported to consist
of two species of approximately 10 and 6 kb in liver, kidney, and
Fig. 6. EGFR mRNA increases with developmental age in C57 and CPK
kidneys. A. Total RNA from 0, 7, 14, and 21 day C57 and CPK kidneys was
subjected to ribonuclease protection analysis as described in the Methods.
Lane P contains unhybridized probe, showing the size of the 32P-labeled
probe fragment alone. Lane L has 32P-labeled 1 kb ladder with fragment
sizes as follows, starting with the darkest upper band: 2,036, 1,636, 1,018,
506/517, 396, 344, 298, 220, 201, 154, and 134 bp. Sizes of the unhybridized
probe and the protected fragments, in bp, are indicated on the figure. Data
are representative of 3 experiments. B. Northern analysis of G3PDH
expression was performed in parallel as described in the Methods, to
assess sample loading equivalence. Size, in kb, is indicated.
several cell lines [25, 36]. Both of these reports utilized a probe
derived from genomic clones that hybridized to the sequences
encoding a region between the kinase domain and the carboxy-
terminal autophosphorylation sites of the EGFR. In the present
study, a riboprobe derived from PCR-amplified eDNA coding for
a region corresponding to a portion of the amino terminus of the
EGFR led to the identification of 3 mRNA species, two of which
correspond to the previously reported mRNA sizes, and a third of
2.7 kb. Although in human A431 cells, the 10 and 5.6 kb EGFR
mRNA species were detected by the murine genomic probe, the
2.8 kb A431 mRNA was not [25]. The 2.8 kb mRNA from A431
cells is a truncated form of the receptor that lacks the transmem-
brane and cytoplasmic domains [24]. In the rat, a truncated
mRNA of 2.7 kb is the predominant mRNA species in liver [37].
Therefore it is possible that the 2.7 kb EGFR mRNA species,
identified in the present study with an "amino-terminal" probe,
also encodes a truncated form of the murine EGFR that was not
detected with the previously described "carboxy-terminal" probe.
The 2.7 kb species appears to be an alternately spliced form,
rather than a novel EGFR gene, since increasing stringency did
not alter the relative intensity of the three hands detected by
Northern analysis. A truncated EGFR is unlikely to be the apical
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Fig. 7. CPK kidneys overexpress EGFR mRNA. The optical densities of the
bands shown in Fig. 6A were quantitated by densitometry as described in
the Methods. The integrated optical densities of each protected fragment
band were normalized to the integrated optical density of the correspond-
ing G3PDH bands from the Northern blot shown in Fig. 6B. Symbols are:
(U) C57; (U) CPK.
form found in CPK kidney since two of the antibodies used to
identify apical EGFR were directed against cytoplasmic se-
quences.
The observation that both C57 and CPK kidneys express the
same developmental pattern and same three species of EGFR
mRNA suggests that the EGFR plays a role in normal renal
function. In CPK mice, the pattern of EGFR mRNA and protein
overexpression also correlates with the appearance of the cystic
phenotype. However, there are differences between the develop-
mental patterns of receptor protein and mRNA expression in
CPK kidneys. It is apparent that CPK EGFR mRNA expression
increased with developmental age and is increased over C57 levels
at all ages, suggesting control at the gene level. These data also
suggest that overexpression of the receptor mRNA in CPK mice
is responsible for the overexpression of EGFR protein detected by
immunostaining and Western blotting. However, with immuno-
staining, an apparent decrease in apical-lateral EGFR expression
was detected at day 21 (Table 1) that may be due to the difficulty
of tubule classification at this age. While large cysts with apical-
lateral EGFR expression are clearly present at 21 days, many of
the proximal and collecting tubule cell surface markers have been
lost. Therefore, 63% apical-lateral expression at 21 days may be
an underestimate of the actual proportion of collecting tubules
affected. By Western analysis CPK EGFR protein expression
appeared to be greatest at 7 days and then decreased. From the
data presented in this study, it is likely that there is complex
regulation of the EGFR in cystic tubular epithelium that may be
cell-specific, and may occur at both the gene and protein levels.
Further studies on the EGFR gene and its regulation, and mRNA
and protein stability, must be undertaken on isolated renal tubular
epithelium. These are necessary since it is not possible to deter-
mine, by the Northern or ribonuclease protection analysis per-
formed, if a coding sequence mutation exists that might lead to
overexpression, missorting, or altered stability of the EGFR.
It is likely that the apical EGFR found in CPK tissue is a
functional tyrosine kinase, based on the following observations.
First, in the present study, EGFR ligand binding and cytoplasmie
determinants were found to be co-localized. Second, preliminary
evidence suggests that the apical CPK EGFR tyrosine kinase can
be activated by EGF. Specific immunoprecipitation of the recep-
tor followed by Western blotting with anti-phosphotyrosine anti-
body detected the same 170 kD protein in both C57 and CPK
kidney tissue and isolated cystic cells incubated with EGF. With-
out EGF incubation, less intense 170 kD bands were detected,
showing that EGF stimulated both the C57 and CPK EGFRs to
become phosphorylated on tyrosine residues [38]. Therefore, in
concert with EGF and the EGF-likc factors found in cyst fluid [7,
9], the CPK EGFR is probably capable of intracellular signalling
in an autoerine-paracrine manner. The high levels of EGFRs at
the apical surfaces of CPK renal cpithelium suggest that these
receptors may be abnormally sorted, may not undergo efficient
ligand-induced down-regulation, or may be more likely to recycle
than normal EGFRs. These overexpressed, apical receptors could
then set off a cascade of intracellular events that would lead to
increased cell proliferation.
The control of normal cell growth by growth factor tyrosine
kinase receptors has recently been reported to be modulated by
the cyclic AMP system at a specific point in the cascade of events
leading to mitogen-activated protein (MAP) kinase activation
[39—44]. The result of crosstalk between these two signaling
systems appears to be inhibition of cell growth in some cases
[40—44], and stimulation in others [39]. Several oncogenes known
to be induced by cAMP are also elevated in PKD models, such as
c-,nyc and c-fos [45, 46]. EGF and cAMP up-regulate EGFR
mRNA expression [47]. In MDCK cells, cAMP stimulates the
formation of large, fluid filled cysts in collagen gel culture [48].
Alterations in the cAMP system have already been associated with
human disease states via mutations in the stimulatory guanine
nucleotide binding protein, Gsa [49, 50]. Therefore, study of the
crosstalk between tyrosine, and cAMP-dependent, protein kinase
systems in cystic renal tissue may provide valuable information
about specific signaling cascades in cyst formation and enlarge-
ment.
EGFR overexpression has been observed in human carcinoma
[51—53], and constitutive activation of the EGFR tyrosine kinase
leads to cell transformation [reviewed in 54]. Mutations in the
CPK EGFR, or defects in a regulatory pathway, might alter
normal EGFR regulation to result in the increased cell prolifer-
ation seen in cystic disease. However, the lesion in PKD is not
simply unregulated cell proliferation which might be expected to
form a tumor, but a fluid-filled cyst. EGF and TGF-a have been
implicated directly in proximal tubular solute transport [55]; and
EGF has also been reported to modulate solute transport [re-
viewed in 55] and vasopressin-induced fluid transport [56] in
collecting tubules. Increased cell proliferation in concert with
altered fluid transport driven by a misplaced EGFR could con-
tribute to the progressive enlargement of collecting tubule cysts
seen in CPK mice. Therefore, we speculate that an overexpressed,
misplaced, apical EGFR may provide a mechanism whereby CPK
collecting tubular epithelium, in concert with mitogenic quantities
of EGF-like peptides in cyst fluid, proliferates to enlarge and form
cysts. Identification of the precise cellular mechanisms responsible
498 Orellana et al: EGF receptor expression in CPK mouse kidney
for cyst formation following EGFR activation may ultimately lead
to the design of potential therapies for human cystic disease
states.
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